NOVOLIN R OTC
Generic Name and Formulations:
Regular insulin (human, rDNA origin) 100 Units/mL; inj.
Indications for NOVOLIN R:
Adults and Children:
SC or IV injection. SC: onset approx 30 mins, peak 2.5–5hrs, duration approx 8hrs.
Instruct patients on diet, exercise, blood or urine testing, proper administration of insulin, change in species of origin, type or purity of insulin, and management of hypoglycemia. Do not reuse or share needles or syringes between patients. Dosage increase may be required during infection, illness, stress, trauma, and pregnancy. Dosage decrease may be needed with renal or hepatic dysfunction.
Concomitant thiazolidinediones (TZDs) may cause fluid retention and heart failure; consider dose reduction or discontinue TZDs. Potentiated by salicylates, MAOIs, alcohol, sulfa drugs, some ACE inhibitors, drugs that inhibit pancreatic function (eg, octreotide), oral hypoglycemic agents, anabolic steroids, quinine, quinidine, alpha-adrenergic blocking agents. Antagonized by corticosteroids, isoniazid, niacin, thiazides, phenothiazines, sympathomimetics, oral contraceptives, thyroid hormones, growth hormone, diazoxide, asparaginase, nicotinic acid. Variable effects with β-blockers, clonidine, lithium salts, alcohol.
Hypoglycemia, hypokalemia, local or systemic allergy, lipodystrophy, edema.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML
- Nicotinamide and Cancer
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma